

REFERENCES

- [1.] AABB technical manual (2011) edn. 17th p227-28
- [2.] AABB pres (2011) Banks, Bethesda, MD edition, p1140 – 1147.
- [3.] Aach RD, et al. (1981); Serum alanine aminotransferase of donors in relation to the risk of non-A, non-B hepatitis in recipients; the transfusion-transmitted Viruses Study. *N Engl J Med*; 4: 989–94.
- [4.] Aggarwal R, Ghoshal UC and Naik SR. (2002) Treatment of chronic hepatitis B with interferon-alpha: cost-effectiveness in developing countries. *Natl Med J India*. 2002, 15, 320-7.
- [5.] Akinbami AA, et al. (2012); Seroprevalence of hepatitis B e antigen (HBe antigen) And B core antibodies (IgG anti-HBcore and IgM anti-HBcore) among hepatitis B surface antigen positive blood donors at a tertiary centre in Nigeria.; *BMC res note*; 28;5(1):167.
- [6.] Allain J, (2005); Occult hepatitis B virus infection. *hep B annual*; 2:14-30.
- [7.] Allain JP, et al (2013) Infectivity of blood products from donors with occult hepatitis B virus infection. *Transfusion* 2013.
- [8.] Allain, J.-P. (2004) Occult hepatitis B virus infection: implications in transfusion. *Vox Sang*, 86, 83–91.
- [9.] Almeida JD, Rubenstein D and Stott EJ (1971) new antigen-antibody system in Australia-antigen-positive hepatitis. *Lancet*, 2(7736):1225–1227.
- [10.] Alter HJ, et al. (1972) Post transfusion hepatitis after exclusion of commercial and hepatitis-B antigen-positive donors. *Ann Intern Med*;77:691–9.
- [11.] Alter HJ, Holland PV and Schmidt PJ, (1970) Hepatitis-associated antigen. To test or not to test? *Lancet*; ii:142–3.
- [12.] Alter M.J. The epidemiology of acute and chronic hepatitis C. *Clin Liver Dis*, 1997. 1(3): 559-68.
- [13.] Alter MJ, et al. (1995) acute non-A-E hepatitis in the United States and Di Bisceglie AM. Hepatitis G virus infection: a work in progress. *Ann Intern Med*; 125:772–3.
- [14.] Alter, H. J. and Houghton, M. (2000) Hepatitis C virus and eliminating post transfusion hepatitis. *Nature Medicine*, 6, 1082–6.
- [15.] Andre, F. (2000) Hepatitis B epidemiology in Asia, the Middle East, and Africa. *Vaccine*, 18, S20–S22.

- [16.] Barbara, J. A. J. (1983) *Microbiology in Blood Transfusion*. Bristol, John Wright, p720-22
- [17.] Bazhenov AI, et al. (2007) Algorithm of serologic screening and assessment of prevalence of serologically meaningful mutations of HBsAg in hepatitis B virus carriers.; *Zh Mikrobiol Epidemiol Immunobiol*. Nov-Dec; (6):30-7.
- [18.] Beeson PB, (1943) Jaundice occurring one to four months after transfusion of blood or plasma, Report of seven cases, *JAMA*; 121: 1332–4.
- [19.] Behzad-Behbahani et al. (2005) Indication of Anti-HBc Antibody Screening and HBV- DNA Detection in Diagnosing Latent Hepatitis B Virus Infection. *Iran Journal of Medical Sciences*; 30(1): 28-33.
- [20.] Berg P, et al (1975) Summary statement of the Asilomar conference on recombinant DNA molecules. *Proc Natl Acad Sci USA*, 72:1981–1984.
- [21.] Bhatti et al, (2007) Removal of Zn(II) ions from aqueous solution using *Moringa oleifera* Lam. (horseradish tree) biomass. *Process Biochem*, 42(4): 547–553.
- [22.] Biswas R, et al. (2003) Comparative sensitivity of HBV NATs and HBsAg assays for detection of acute HBV infection. *Transfusion*; 43:788-98.
- [23.] Blackburn, 1991 (1974)
- [24.] Blumberg BS, Alter HJ and Visnich S. A (1965) “New” antigen in leukaemia sera. *JAMA*; 191:541–6.
- [25.] Bouchardeau F, et al. (2006) Sensitivity of hepatitis B virus DNA transcription-mediated amplification testing in hepatitis B surface antigen-positive blood donations.; *Transfusion*. Dec; 46(12): 2047-52.
- [26.] Bounaud, (1987) chemiluminescence immunoassay of thyrotropin with acridinium-ester-labeled antibody evaluated and compared with two other immunoassays. *clinical chem*, 1012-7.
- [27.] Buckwold V. E, et al. (1996) Effects of a naturally occurring mutation in the hepatitis B virus basal core promoter on precore gene expression and viral replication. *J. Virol*. 70, 5845–5851.
- [28.] Busch MP, et al. (1995) declining value of alanine aminotransferase in screening of blood donors to prevent post transfusion hepatitis B and C virus infection, *Transfusion*; 35:903–10.
- [29.] Busch MP. (2004) Should HBV DNA NAT replace HBsAg and/or anti-HBc screening of blood donors? *Transfus Clin Biol*, 11, 26–32.

- [30.] Carman, W. F., et al. (1990) Vaccine-induced escape mutant of hepatitis B virus. *Lancet* 336, 325–329.
- [31.] Chakrabarti S and Chakravarty R. (2010) Anti-hepatitis B core antigen testing with detection and characterization of occult hepatitis B virus by an in-house nucleic acid testing among blood donors in Behrampur, Ganjam, Orissa in southeastern India: implications for transfusion. *Virol J.* Aug 27; 7:204.
- [32.] Chaudhuri V, Nanu A, Panda SK, Chand P. (2003); Evaluation of serologic screening of blood donors in India reveals a lack of correlation between anti-HBc titer and PCR- amplified HBV DNA. *Transfusion*, 43, 1442-1448.
- [33.] Cheng Y, et al. (1999) Dubovoy N, Hayes-Rogers ME, Stewart J, Shah D.; Detection of IgM to hepatitis B core antigen in a reductant containing, chemiluminescence assay.; *J Immunol Methods.* Nov 19; 230 (1-2):29-35.
- [34.] Choo QL, et al. (1989) isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. *Science*; 244:359–61.
- [35.] Coffin CS, et al. (2004) persistence of isolated antibodies to woodchuck hepatitis virus core antigen is indicative of occult infection. *Hepatology*; 40:1053-61.
- [36.] Comanor, L. and Holland, P. (2006) Hepatitis B virus blood screening: unfinished agendas. *Vox Sang*, 91, 1–12.
- [37.] Conjeevaram et al, (2008) A randomized, double-blind, placebo-controlled study of PPAR gamma agonist pioglitazone given in combination with peginterferon and ribavirin in patients with genotype-1 chronic hepatitis C. *Hepatology* 48: 384A–384A
- [38.] Dane DS, Cameron CH and Briggs M (1979) Virus-like particles in serum of patients with Australia-antigen-associated hepatitis. *Lancet*, 1(7649):695–698.
- [39.] Danvey JR, (2004) Recruiting blood donors: challenges and opportunities. *Transfusion*; 44: 597-600.
- [40.] Dhawan HK, et al. (2008) Anti-HBc screening in Indian blood donors: still an unresolved issue; *World J Gastroenterol.* Sep 14;14(34):5327-30.
- [41.] Di Bisceglie AM, (1996) Hepatitis G virus infection: a work in progress. *Ann Intern Med*; 125:772–3.
- [42.] Dienstag JL, et al (1995) A preliminary trial of lamivudine for chronic hepatitis B infection. *N Engl J Med*, 333:1657–1661.

- [43.] Dodd, R. Y. (2003) Emerging infections, transfusion safety, and epidemiology. *N Eng J Med*, 349, 1205–6.
- [44.] Domen RE, (1995) Paid-versus-volunteer blood donation in the United States: a historical review. *Transfus Med Rev*; 9:53–9.
- [45.] Dow BC, Yates P and Galea G, (2002) Munro H, Buchanan I, Ferguson K. Hepatitis B vaccinees may be mistaken for confirmed hepatitis B surface antigen-positive blood donors. *Vox Sang*; 82:15-7.
- [46.] Dow BC, Yates P, Galea G, Munro H, Buchanan I, Ferguson K. (2002) Hepatitis B vaccinees may be mistaken for confirmed hepatitis B surface antigen-positive blood donors. *Vox Sang.*, 82, 15-7.
- [47.] Dreier, J., Kroger, M., Diekman, J., et al. (2004) Low-level viraemia of hepatitis B virus in an anti-HBc- and anti-HBs-positive blood donor. *Transfus Med*, 14, 97–103.
- [48.] Duseja A. (2006) Nonalcoholic fatty liver disease in India—is it different? *Trop Gastroenterol* 27: 142–146
- [49.] Engvall and Perlmann, (1971) Enzyme-linked immunosorbent assay (ELISA). Quantitative assay of immunoglobulin G. *Immunochemistry*. 1971 Sep;8(9):871-4.
- [50.] Ezzell C, (1988) Candidate cause identified of non-A, non-B hepatitis [News]. *Nature*; 333:195.
- [51.] Farci PF, (2006) Evolution of hepatitis C viral quasispecies and hepatic injury in perinatally infected children followed prospectively; *Proc Natl Acad Sci U S A*. May 30; 103(22): 8475–8480.
- [52.] Feinstone SM, Kapikian AZ and Purcell RH (1975) Transfusion-associated hepatitis not due to viral hepatitis A or B. *N Engl J Med* 292:767–770
- [53.] France AM, et al (2012) Estimating the Prevalence of Chronic Hepatitis B Virus Infection-New York City, 2008. *J Urban Health*, Jan 13.
- [54.] Galbraith et al. (1975) Fulminant hepatic failure in leukaemia and choriocarcinoma related to withdrawal of cytotoxic drug therapy. *Lancet* 1975, 2(7934):528–530.
- [55.] Ganem D, (1991) Assembly of hepadnaviral virions and subviral particles. *Curr Top Microbiol Immunol*; 168:61-83.

- [56.] Gerlich WH, and Lüer W (1979) Selective detection of IgM-antibody against core antigen of the hepatitis B virus by a modified enzyme immune assay. *J Med Virol* 1979,4:227–238.
- [57.] Gerlich WH, Glebe D and Schuttler CG. (2007) Deficiencies in the standardization and sensitivity of diagnostic tests for hepatitis B virus. *J Viral Hepat*; 14(Suppl 1):16- 21.
- [58.] Giri P A, Yadav S, Parhar G S and Phalke D B. (2011) Frequency of ABO and Rhesus Blood Groups: A Study from a Rural Tertiary Care Teaching Hospital in India. *Int J Biol Med Res*; 2 (4): 988–990.
- [59.] Gish R A (1997) simple and inexpensive point-of-care test for hepatitis B surface antigen detection: serological and molecular evaluation; *Journal of Viral Hepatitis*; 21(12)905–908.
- [60.] Gocke DJ, et al (1970) correlation of Australia antigen with post transfusion hepatitis. *JAMA*; 77:877–9.
- [61.] Gordeuk VK, et al. (1990) prevention of iron deficiency with carbonyl iron in female blood donors. *Transfusion*; 30: 239-45.
- [62.] Grady GF and Chalmers TC. (1964) Risk of post-transfusion viral hepatitis. *N Engl J Med*; 271:337–42.
- [63.] Gunther, S., et al. (1999) naturally occurring variants of hepatitis B virus. *Adv. Virus Res.* 52, 25–137.
- [64.] Gurtler et al. 1995 *Bergey's Manual of Systematic Bacteriology: Volume 5: The Actinobacteria* 439-446.
- [65.] Gust, et al., 1983 The origin of the HM-175 strain of hepatitis A virus. *Journal of infectious diseases* 151, 365-366.
- [66.] Hadziyannis, (1997) *Journal of Gastroenterology and Hepatology*; Volume 12, Issue 4, pages 289–298.
- [67.] Hartsfield J. (1998) Iron status in the female blood donor. *Nutrition Bytes*; 4: 1-5.
- [68.] Heermann KH, et al. (1999) Quantitative detection of hepatitis B virus DNA in two international reference plasma preparations. *J Clin Microbiol*; 37:68-73.
- [69.] Hollinger FB, (2008) Hepatitis B virus infection and transfusion medicine: science and the occult. *Transfusion* 48, 1001–1016.
- [70.] Hollinger FB. (2007) Hepatitis B virus genetic diversity and its impact on diagnostic assays. *J Viral Hepat*; 14(Suppl 1):11-5.

- [71.] Hoofnagle J H, et al. (1978) Type B hepatitis after transfusion with blood containing antibody to hepatitis B core antigen. *N Engl J Med*; 298: 1379-83.
- [72.] Hoofnagle JH. (1990) Post transfusion hepatitis B [Editorial]. *Transfusion*; 30:384–6.
- [73.] Hourfar MK, et al. (2009) Sensitivity and specificity of Anti-HBc screening assays--which assay is best for blood donor screening?; *Int J Lab Hematol*; Dec;31(6):649-56.
- [74.] Iudicone P, et al (2009) Hepatitis B virus blood screening, impact of nucleic amplification technology testing implementation on identifying hepatitis B surface antigen non-reactive window period and chronic infections. *Vox Sang.*, 96, 292-7.
- [75.] J. Donald Coonrod (edn. 2012) *The Direct Detection of Microorganisms in Clinical Samples*, p240-255.
- [76.] Jackson et al. (2003) Diversity in social context: A multi-attribute, multi-level analysis of team diversity and performance in a sales organization. Unpublished manuscript, Rutgers University, New Brunswick, NJ.
- [77.] Jashnani KD, Patil LN. (2011) Blood donor deferrals: Can this be reduced? *Asian J Transfus Sci.*;5:60. Jongerius et al. 1998
- [78.] Kann, M., and Gerlich, W.H. (2005) *Hepatitis B Virus and Other Hepadnaviridae. Structure and Molecular Virology*. Edinburgh, London, Madrid, Melbourne, New York, Tokyo: Churchill Livingstone.
- [79.] Kao JH, et al. (2002) Occult Hepatitis B Virus Infection and Clinical Outcomes of Patients with Chronic Hepatitis C. *Journal of Clinical Microbiology*; 40: 4068-4071.
- [80.] Kao, J. H., et al. (2000) Hepatitis B genotypes and the response to interferon therapy. *J. Hepatol.* 33, 998–1002.
- [81.] Khalid A. et al (2001) the frequency and significance of isolated hepatitis B core antibody and the suggested management of patients; *CMAJ*, 165:1063-1064.
- [82.] Kimura, T., Rokuhara, A., Matsumoto, A., et al. (2003) New enzyme immunoassay for detection of hepatitis B virus core antigen (HBcAg) and relation between levels of HBcAg and HBV DNA. *J Clin Microbiol*, 41, 1901–6.

- [83.] Klein, H. G. (2005) Pathogen inactivation technology: cleansing the blood supply. *J Intern Med*, 257, 224–37.
- [84.] Kleinman S, Busch M, Rawal B and Glynn S, (1998) Evaluation of HBsAg neutralization test positive (neut pos) donors with negative (neg) anti-HBc. *Transfusion*; 38(Suppl):92S.
- [85.] Kleinman SH and Busch MP. (2006) Assessing the impact of HBV NAT on window period reduction and residual risk. *J Clin Virol*; 36:S23-S29.
- [86.] Kleinman SH, et al (2005) Hepatitis B virus (HBV) DNA screening of blood donations in mini-pools with the COBAS AmpliScreen HBV test. *Transfusion*, 45, 1247–57.
- [87.] Kleinman SH, et al. (2003) Frequency of HBV DNA detection in US blood donors testing positive for the presence of anti-HBc: implications for transfusion transmission and donor screening. *Transfusion*; 43:696-704.
- [88.] Krivopustova AV. (1995) Possibilities of indication of anti-Hb core IGM in the saliva of patients with hepatitis B; *Klin Lab Diagn*; (5):20-1.
- [89.] Krugman S, Giles JP and Hammond J (1967) Infectious hepatitis. Evidence for two distinctive clinical, epidemiological, and immunological types of infection. *JAMA*, 200:365–373.
- [90.] Kumar H, Gupta PK and Jaiprakash M. (2007) The role of anti-HBc IgM in screening of blood donors; *MJAFI*; 63: 350-352.
- [91.] Kusum D Jashnani and Laxmi N Patil, (2011) Blood donor deferrals: Can this be reduced; *Asian Journal of Transfusion Sci* (1)60
- [92.] Kwok S and Higuchi R. (1989) Avoiding false positives with PCR. *Nature*; 339:237-8.
- [93.] Kwok, S. and Higuchi, R. (1989) Avoiding false positives with PCR. *Nature*, 339, 237–8.
- [94.] Lok, A. S., Akarca, U., and Greene, S. (1994) Mutations in the pre-core region of hepatitis B virus serve to enhance the stability of the secondary structure of the pre-genome encapsidation signal. *Proc. Natl. Acad. Sci. U S A* 91, 4077–4081.
- [95.] Lu SN, et al. (2003): Molecular epidemiological and clinical aspects of hepatitis D virus in a unique triple hepatitis viruses (B, C, D) endemic community in Taiwan. *J Med Virol*, 70:74-80.

- [96.] Lürmann, A (1885) Eine icterusepidemie. *Ber Klin Wochenschr* 1885, 22:20–23.
- [97.] MacCallum, (1971) International symposium on viral hepatitis. Historical perspectives. *Can Med Assoc J*, 106(Suppl):423–426.
- [98.] Makroo RN, et al. (2012) Hepatitis B core antibody testing in Indian blood donors: A double-edged sword!; *Asian J Transfus Sci.*; 6(1):10-3.
- [99.] Makroo, RN, et al (2007) Occult Hepatitis B Virus Infection among Blood donors of North India. *Apollo Medicine*, 2007; 4:339
- [100.] Marantidou O, et al. (2007) Factors that motivate and hinder blood donation in Greece. *Trans Med*; 17: 443-50.
- [101.] Marantidou, et al., 2007
- [102.] Mason, et al (2012) Family Hepadnaviridae. *Virus taxonomy, ninth report of the international committee on taxonomy of viruses*. Amsterdam: Elsevier; 445–455.
- [103.] Milich DR, McLachlan A (1986) The nucleocapsid of hepatitis B virus is both a T-cell- independent and a T-cell-dependent antigen. *Science* 1986, 234:1398–1401.
- [104.] Millman I, Loeb LA and Bayer ME, (1970) Blumberg BS: Australia antigen (a hepatitis- associated antigen): purification and physical properties. *J Exp Med*, 131:1190–1199.
- [105.] Mine H, et al. (2003) High throughput screening of 16 million serologically negative blood donors for hepatitis B virus, hepatitis C virus and human immunodeficiency virus type-1 by nucleic acid amplification testing with specific and sensitive multiplex reagent in Japan. *J Virol Methods*; 112: 145-51.
- [106.] Minegishi, K., Yoshikawa, A., Kishimoto, S., et al. (2003) Superiority of minipool nucleic acid amplification technology for hepatitis B virus over chemiluminescence immunoassay for hepatitis B surface antigen screening. *Vox Sang*, 84, 287–91.
- [107.] Mosley JW, et al. (1995) Donor levels of serum alanine aminotransferase activity and antibody to hepatitis B core antigen associated with recipient hepatitis C and non-B, non-C outcomes. *Transfusion*; 36: 776–81.
- [108.] Mushahwar IK, et al. (1981) Interpretation of various serological profiles of hepatitis B virus infection. *Am J Clin Pathol*; 76:773-7.

- [109.] NACO guideline, 2007, p20
- [110.] Nelson et al., (1993) Efficacy of donor screening methods on reducing the risk of transfusion-transmission of hepatitis C virus. Fourth International Symposium on HCV, Tokyo, 40 (abstract).
- [111.] Newman BH. (2004) Adjusting our management of female blood donors: the key to an adequate blood supply. *Transfusion*; 44: 591-6.
- [112.] NIH (1995) Infectious disease testing for blood transfusions. NIH Consensus Statement Jan 9–11; 13:1–27.
- [113.] Okamoto, H., et al. (1994) Hepatitis B virus with mutations in the core promoter for an e antigen-negative phenotype in carriers with antibody to e antigen. *J. Virol.* 68, 8102–8110.
- [114.] Orito, E., et al. (2001) A case-control study for clinical and molecular biological differences between hepatitis B viruses of genotypes B and C. Japan HBV Genotype Research Group. *Hepatology* 33, 218–223.
- [115.] Panigrahi R, et al (2010) Anti-hepatitis B core antigen testing with detection and characterization of occult hepatitis B virus by an in house nucleic acid testing among blood donors in Behrampur, Ganjam, Orissa in southeastern India: implications for transfusion. *Virology*, 7, 204.
- [116.] Pasek, et al., (1979) Hepatitis B virus genes and their expression in *E. coli*. *Nature*, 282:575–579.
- [117.] Patel Piyush A, Patel Sangeeta P, Shah Jigesh V and Oza Haren V, (2012) Frequency and distribution of blood groups In blood donors in western ahmedabad – a Hospital based study; *National Journal of Medical Research*; 2(2) p202-206.
- [118.] Pereira, A. (2003) Health and economic impact of post-transfusion hepatitis B and cost-effectiveness analysis of expanded HBV testing protocols of blood donors: a study focused on the European Union. *Transfusion*, 43, 192–201.
- [119.] Previsani, N., Lavanchy, D. and Siegl, G. (2004) Hepatitis A. In *Viral Hepatitis: Molecular Biology, Diagnosis, Epidemiology and Control (Perspectives in Medical Virology, volume 10)*, ed. I. K. Mushahwar, pp. 1–98. Amsterdam, Elsevier.
- [120.] Prince, A., Lee, D.-H. and Brotman, B. (2001) Infectivity of blood from PCR positive, HBsAg-negative, anti-HBs positive cases of resolved hepatitis B infection. *Transfusion*, 41, 329–32.

- [121.] Rabeya Y, et al. (2008) Blood pre - donation deferrals - a tertiary hospital Experience. *Southeast Asian Journal of Tropical Medicine and Public Health*; 39:571-4
- [122.] Raimondo G, et al (2008) Statements from the Taormina expert meeting on occult hepatitis B virus infection. *J Hepatol*, 49:652–657.
- [123.] Ramachandran, et al., (2001) National Urban Diabetes Survey; *Diabetologia*; 44:1094-1101.
- [124.] Robertson EF, et al. (1991) Characterization of a reduction-sensitive factor from human plasma responsible for apparent false activity in competitive assays for antibody to hepatitis B core antigen. *J Clin Microbiol*; 29:605-10.
- [125.] Robinson, et al., 1974) DNA of a human hepatitis B virus candidate. *J Virol*, 14:384–391.
- [126.] Roth, W. K., Weber, M., Petersen, D., et al. (2002) NAT for HBV and anti-HBc testing increase blood safety. *Transfusion*, 42, 869–75.
- [127.] Schmidt M, et al. (2006) Anti-HBc screening of blood donors: a comparison of nine anti-HBc tests.; *Vox Sang.*; 91(3):237-43.
- [128.] Schreiber GB, et al. (2006) Convenience, the bane of our existence, and other barriers to donating. *Transfusion*; 46:545-53.
- [129.] Seeff et al., (1987) A serologic follow-up of the 1942 epidemic of post-vaccination hepatitis in the United States Army. *N Engl J Med.*, 316:965–970.
- [130.] Seitz S, et al., (2007) Cryo-electron microscopy of hepatitis B virions reveals variability in envelope capsid interactions. *EMBO J*, 26:4160–4167.
- [131.] Sharma S, et al. (2006) Prolonged hepatitis B surface antigen positivity in hepatitis B vaccine recipients. *Dig Liver Dis.*; 38:860-1.
- [132.] Shastry and S.S. Bhat (2011). Prevention of Post-Transfusion Hepatitis by Screening of Antibody to Hepatitis B Core Antigen in Healthy Blood Donors; *Mediterr J Hematol Infect Dis.*; 3(1): e2011062.
- [133.] Silva MA, ed. (2005) Standards for blood banks and transfusion services. 23rd ed. Bethesda, MD: AABB.
- [134.] Simons JN, et al (1995) Isolation of novel virus-like sequences associated with human hepatitis. *Nat Med*; 1:564–9.
- [135.] Snyder, E. L. and Dodd, R. Y. (2001) Reducing the risk of blood transfusion. *Hematology (Am Soc Hematol Educ Program)*, 433–42.

- [136.] Soldan, K., Barbara, J. A. J. and Dow, B. C. (2002) Transfusion-transmitted hepatitis B virus infection in the UK: a small and moving target. *Vox Sang*, 83, 305–8.
- [137.] Standards for Blood Banks & Blood Transfusion Services, 2007, p20
- [138.] Stevens CE, et al. (1978) Serologic evidence of hepatitis A and B virus infections in thalassemia patients: a retrospective study. *Transfusion*; 18:356–60.
- [139.] Stramer SL, et al (2011) Nucleic acid testing to detect HBV infection in blood donors. *N Engl J Med.*,364,236-47.
- [140.] Stramer SL, et al. (2012) Blood donation screening for hepatitis B virus markers in the era of nucleic acid testing: are all tests of value? *Transfusion*; 52(2):440-6.
- [141.] Stramer SL. (2005) Pooled Hepatitis B Virus DNA testing by nucleic acid amplification, implementation or not. *Transfusion*, 45, 1242–6.
- [142.] Tegtmeier GE, Katz LM, Stramer SL and Strong DM. (2007) Feasibility of reentry of donors deferred for repeated detection of antibody to hepatitis B core antigen (anti-HBc). *Transfusion*; 47(Suppl):30A.
- [143.] Usuda, S., et al. (1999) Serological detection of hepatitis B virus genotypes by ELISA with monoclonal antibodies to type-specific epitopes in the preS2-region product. *J, Virol, Methods* 80, 97–112.
- [144.] Usuda, S., et al. (2000) Differentiation of hepatitis B virus genotypes D and E by ELISA using monoclonal antibodies to epitopes on the preS2-region product. *J, Virol, Methods* 87, 81–89.
- [145.] Velati C, et al (2008) Impact of nucleic acid testing for hepatitis B virus, hepatitis C virus, and human immunodeficiency virus on the safety of blood supply in Italy: a 6-year survey. *Transfusion*, 10, 2205-13.
- [146.] Vermeulen M, et al. (2012) Hepatitis B virus transmission by blood transfusion during 4 years of individual-donation nucleic acid testing in South Africa: estimated and observed window period risk. *Transfusion*; 52(4):880-92.
- [147.] Walsh JH, et al (1970) Post transfusion hepatitis after open-heart operations. Incidence after the administration of blood from commercial and volunteer donor populations. *JAMA*; 211:261–5.

- [148.] WHO. Guideline for drinking water quality, recommendation, vol 1, 2nd ed. World Health Organization, Geneva. 1992; 41.
- [149.] Will H et al., (1982) Cloned HBV DNA causes hepatitis in chimpanzees. *Nature*, 299:740–742.
- [150.] Wittkop L, et al., (2010) Inhibition of protein kinase C phosphorylation of hepatitis B virus capsids inhibits virion formation and causes intracellular capsid accumulation. *Cell Microbiol*, 12:962–975.
- [151.] Wolfram H Gerlich, (2013) Medical Virology of Hepatitis B: how it began and where we are now, *Gerlich Virology Journal* 2013, 10:239.
- [152.] Yao JD, et al. (2004) Multicenter evaluation of the VERSANT hepatitis B virus DNA 3.0 assay. *J Clin Microbiol*; 42: 800-6.
- [153.] Yotsuyanagi H, et al (2001) frequent presence of HBV in the sera of HBsAg-negative, anti-HBc- positive blood donors, *Transfusion*, 41, 1093-1099.
- [154.] Zaaijer, H. L., Vrieling, H. and Koot, M. (2001) early detection of hepatitis B surface antigen and detection of HBsAg mutants: a comparison of five assays. *Vox Sang*, 81, 219–21.
- [155.] Zarski JP, Bohn B, and Bastie A (1998): Characteristics of patients with dual infection by hepatitis B and C viruses. *J Hepatol*; 28:27-33.
- [156.] Zou S, et al. (2008): Donor deferral and resulting donor loss at the American Red Cross Blood Services, 2001 through 2006. *Transfusion*; 48: 2531-9.
- [157.] Zuckerman AJ. (1996) Alphabet of hepatitis viruses; *Lancet*; 347:558–9.